Asro
The Committee representing major stakeholders in the pharmaceutical sector has issued a comprehensive set of policy recommendations aimed at fortifying Taiwan’s healthcare infrastructure, ensuring the long-term sustainability of the National Health Insurance (NHI) system, and elevating the nation’s standing in the global biotechnology landscape. As Taiwan navigates a complex intersection of shifting geopolitical dynamics and evolving economic pressures, the Committee emphasizes that the current pharmaceutical pricing structure must be modernized to prevent supply instabilities and ensure that Taiwanese patients maintain timely access to the world’s most innovative medical therapies. This call for reform comes at a pivotal moment in Taiwan-U.S. relations, specifically regarding healthcare cooperation, where deeper public-private partnerships are viewed as the primary engine for future growth and resilience.
Contextual Background: The Evolution of Taiwan’s Healthcare Ambitions
Taiwan’s National Health Insurance (NHI) system, established in 1995, is globally recognized for its universal coverage and high efficiency. However, the system has faced increasing financial pressure due to an aging population and the rising costs of advanced medical technologies. Under the administration of President Lai Ching-te, the "Healthy Taiwan" initiative has been launched to prioritize public health, with a specific focus on significantly improving cancer survival rates. Parallel to this, the administration has identified biotechnology as one of the "Five Trusted Industries," alongside semiconductors and artificial intelligence, signaling a strategic shift toward making Taiwan a global hub for healthcare innovation.
Despite these ambitions, the pharmaceutical industry has raised concerns regarding the "Taiwan gap"—a delay in the introduction of new drugs compared to other advanced economies. Currently, the time from global market launch to NHI reimbursement in Taiwan can take significantly longer than in the United States or Europe. The Committee’s recommendations are designed to bridge this gap by aligning domestic pricing and regulatory frameworks with international standards, thereby incentivizing multinational pharmaceutical companies to prioritize the Taiwan market.
Chronology of Recent Bilateral and Domestic Developments
The push for these reforms is set against a backdrop of significant milestones in Taiwan’s trade and healthcare policy over the past 24 months:
- June 2023: The first agreement under the U.S.-Taiwan Initiative on 21st-Century Trade was signed, laying the groundwork for deeper regulatory cooperation and customs streamlining.
- Late 2023: Taiwan achieved a breakthrough in trade negotiations with the United States, securing duty-free treatment for Taiwanese generic drugs and active pharmaceutical ingredients (APIs) in the U.S. market.
- May 2024: President Lai Ching-te took office, reaffirming the "Healthy Taiwan" vision and the goal of reducing cancer mortality by one-third by 2030.
- Budget Planning 2024-2025: The government announced the establishment of a dedicated Cancer Drugs Fund (CDF), with a target of reaching NT$10 billion by 2025 to provide earlier access to innovative oncology treatments.
- Legislative Amendments: Recent updates to Article 27 of the Pharmaceutical Affairs Act have shifted the focus from reactive shortage management to proactive risk monitoring for drug supplies.
Formalizing U.S.-Taiwan Policy Dialogue and International Alignment
One of the Committee’s primary recommendations is the establishment of a regularized, formal policy dialogue mechanism between the United States and Taiwan. While the recent duty-free agreements for generics represent a major victory for the domestic industry, the Committee argues that a more structured platform is necessary to manage the complexities of innovative medicine. This proposed "U.S.-Taiwan Pharmaceutical Policy Dialogue" would include government representatives, manufacturers, and academic experts to discuss regulatory alignment, pricing trends, and the introduction of new therapies.
To support this, the Committee suggests that the National Health Insurance Administration (NHIA) conduct biannual consultations with the industry. These meetings would serve as a "horizon scanning" exercise, allowing the government to anticipate international economic shifts that might impact drug pricing. Furthermore, the Committee proposes leveraging the Global Cooperation and Training Framework (GCTF) to showcase Taiwan’s healthcare governance on the world stage, effectively using its domestic strengths as a tool for "soft power" diplomacy.
A critical component of this international alignment is the harmonization of drug reimbursement conditions with global treatment guidelines. Currently, many non-cancer medicines and even some oncology therapies in Taiwan face restrictive reimbursement criteria, such as limitations on patient eligibility or treatment duration. The Committee warns that these misalignments not only hinder patient care but also discourage international clinical trials from taking place in Taiwan, as the local standard of care does not match the global protocol.
Ensuring Fair R&D Cost-Sharing and Value-Based Pricing
The sustainability of the NHI system depends on a fair and predictable pricing environment. The Committee welcomes the NT$10 billion Cancer Drugs Fund but stresses that its success depends on evidence-based funding mechanisms. Rather than relying on static, short-term data, the Committee recommends a medium-to-long-term budgeting approach that incorporates "horizon scanning" to anticipate future breakthroughs and allocate resources with greater precision.
To maintain Taiwan’s advantage in attracting new drug launches, the Committee suggests a review of the NHI Pharmaceutical Reimbursement and Payment Standards. Specifically, they advocate for:
- Median Pricing: Setting prices based on the median of 10 reference countries to ensure Taiwan remains a competitive market.
- Value-Based Adjustments: Introducing price premiums that reflect a drug’s clinical effectiveness, safety improvements, and convenience, as well as incentives for companies that conduct domestic clinical trials or establish R&D centers in Taiwan.
- Predictable Reimbursement Agreements: Moving away from short-term financial controls like hard spending caps and excessive rebates. The Committee notes that if prices in Taiwan are compressed too severely, it can negatively impact a drug’s global reference price, leading companies to deprioritize Taiwan in their global launch sequences.
Strengthening Lifecycle Management and Supply Resilience
A significant portion of the Committee’s report focuses on the lifecycle management of pharmaceuticals. A point of contention is the Drug Expenditure Target (DET) system, a pilot budget control mechanism. The Committee points out that the baseline value used for DET calculations has remained unchanged for over a decade, failing to reflect the actual rising costs of modern healthcare. This creates distorted pricing signals that can lead to drug shortages, undermining the very resilience the government seeks to build.
Furthermore, the Committee expressed concerns regarding Intellectual Property (IP) protection within the pricing framework. Currently, price protection is often limited to drugs with primary active-ingredient patents. The Committee argues that this ignores the internationally recognized scope of patents, leading to premature price reductions for innovative medicines that still hold valid secondary patents. Such practices undermine the "lifecycle value" of a drug and serve as a deterrent for companies considering Taiwan for new product launches.
Regarding the recent amendments to the Pharmaceutical Affairs Act, the Committee supports the shift toward proactive risk management but cautions against "excessive administrative burdens." They recommend a risk-based approach to supply monitoring, where products with a history of stable supply are not subjected to the same rigorous reporting requirements as those at high risk of shortage.
Fact-Based Analysis of Implications and Future Outlook
The implications of these recommendations extend far beyond the pharmaceutical industry. If adopted, these reforms could catalyze a significant increase in Foreign Direct Investment (FDI) from the global life sciences sector. By aligning with international standards, Taiwan positions itself as a "trusted partner" in the global supply chain—a status that is increasingly valuable as Western nations seek to diversify their pharmaceutical dependencies.
From a public health perspective, the alignment with international guidelines and the stabilization of the Cancer Drugs Fund could result in a measurable decrease in mortality rates for chronic and terminal illnesses. For the NHI system, moving toward a value-based pricing model ensures that taxpayer money is spent on treatments that provide the highest clinical return, rather than simply the lowest cost.
However, the path forward requires a delicate balance. The NHIA must manage a finite budget while meeting the high expectations of the "Healthy Taiwan" vision. The Committee’s proposal for a "regularized policy dialogue" offers a pragmatic solution to this tension, providing a forum where financial constraints and medical innovation can be reconciled through transparent, data-driven negotiation.
In conclusion, the Committee’s recommendations represent a roadmap for transforming Taiwan’s healthcare system from a cost-center into a strategic asset. By fostering a predictable investment environment, protecting intellectual property, and deepening international collaboration, Taiwan can ensure that its citizens have access to the best medical care in the world while simultaneously driving the next wave of domestic economic growth in the biotechnology sector. The transition to a more resilient and competitive pharmaceutical landscape is not merely an industry request; it is a fundamental requirement for the long-term health and security of the nation.
Siti Muinah
Layla Zulfa
